IGFBP-1 Antibody (176110) [Alexa Fluor® 350]

• Reactivity: Mu
• Applications: WB
• Clone: 176110
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 350

IGFBP-1 Antibody (176110) [Alexa Fluor® 350] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse IGFBP-1
  Ala26-Asn272
  Accession # P47876
• Specificity: Detects mouse IGFBP-1 in direct ELISAs and Western blots. In Western blots, weak cross-reactivity with recombinant mouse (rm) IGFBP-5 is observed and no cross-reactivity with recombinant human (rh) IGFBP-1, rmIGFBP-2, rmIGFBP-3, rhIGFB
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGFBP-1 Antibody (176110) [Alexa Fluor® 350]

• alpha-pregnancy-associated endometrial globulin
• amniotic fluid binding protein
• binding protein-25
• binding protein-26
• binding protein-28
• growth hormone independent-binding protein
• hIGFBP-1
• IBP1
• IBP-1
• IGF-binding protein 1
• IGFBP1
• IGFBP-1
• IGF-BP25
• insulin-like growth factor binding protein 1
• insulin-like growth factor-binding protein 1
• Placental protein 12
• PP12AFBP

Background

The insulin-like growth factor binding protein (IGFBP) family consists of six structurally related proteins that bind IGF with high affinity (1, 2). These proteins share conserved cysteine-rich N- and C- terminal regions that participate in IGF binding. IGFBPs regulate the bioavailability of IGFs and modulate their biological activities, both positively and negatively. Some IGFBPs also have intrinsic bioactivity that is IGF-independent. Post-transitional modifications of the IGFBPs, including glycosylation, phosphorylation and proteolysis, influence IGF binding affinities and tissue localization, affecting both the IGF-dependent and independent functions (1, 2). Mouse IGFBP-1 cDNA encodes a 272 amino acid (aa) precursor protein with a putative 25 aa signal peptide (3). Mature mouse IGFBP-1 contains potential phosphorylation and proteolytic cleavage sites, an Arg-Gly-Asp (RGD) integrin receptor recognition sequence, but lacks potential N-linked glycosylation sites. IGFBP‑1 binds equally well to IGF-I and IGF-II. Phosphorylation of human IGFBP-1, but not rat IGFBP-1, increases IGF affinity. Mouse IGFBP-1 shares 67% and 93% aa sequence identity with human and rat IGFBP-1, respectively. IGFBP-1 is expressed in liver, decidua, and kidneys and is the most abundant IGFBP in amniotic fluid. Hepatic production of IGFBP-1 is down-regulated by insulin and up-regulated by glucocorticoids. Circulating IGFBP-1 levels are elevated under various catabolic conditions including bacterial or viral infections, trauma and diabetes (4). IGFBP-1 has been shown to either potentiate or inhibit the activities of IGF in a variety of cells. IGFBP-1, through its RGD motif, also interacts with alpha 5 beta 1 intergrin to stimulate changes in cell adhesion and migration in the absence of IGFs (1, 2).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.